Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glivec + MTC in Refractory/Relapsed AML
NCT00744081Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Jul 2004
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in acute myeloid leukemia (AML), sponsored by Goethe University Frankfurt. Started Jul 2004; status: completed.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00744081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00744081.